• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Ablynx - Articles and news items

Ablynx initiates Phase IIb anti-RSV nanobody trial for infants

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

Topline results from this Phase IIb study to treat children with RSV with inhaled ALX-0171 are expected in the second half of 2018…

Ablynx starts Phase III follow-up aTTP study

Industry news / 13 October 2016 / Niamh Louise Marriott, Digital Content Producer

Acquired TTP is an acute, ultra-rare, life-threatening blood clotting disorder in which uncontrolled platelet aggregation and microclot formation cause…

Positive top line results from ALX-0171 infant RSV study

Industry news / 4 May 2016 / Victoria White, Digital Content Producer

The study met its primary endpoint, demonstrating the favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation…

Results from TITAN study of caplacizumab published

Industry news / 11 February 2016 / Victoria White

Results from Ablynx’s worldwide Phase II TITAN study with caplacizumab for patients with acquired thrombotic thrombocytopenic purpura (aTTP) have been published…

Edwin Moses, Chief Executive Officer, Ablynx

Ablynx announces half-year results for 2015

Industry news / 27 August 2015 / Nick Jackson

Ablynx has announced its business update and results for the six-month period ending 30 June 2015…